<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1858">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636086</url>
  </required_header>
  <id_info>
    <org_study_id>D-COVID</org_study_id>
    <nct_id>NCT04636086</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection</brief_title>
  <official_title>Vitamin D Supplementation and Covid-19: a Randomised, Double- Blind, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoires SMB S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the clinical efficacy and safety of vitamin D&#xD;
      supplementation in hospitalized patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase IV, interventional, randomised, double blind, placebo-controlled and parallel study to&#xD;
      evaluate the clinical efficacy and safety of vitamin D supplementation in hospitalized&#xD;
      patients with COVID-19.&#xD;
&#xD;
      Patients will participate in the study for a maximum of 9 weeks, which includes an up to&#xD;
      6-week treatment period and a maximum of 3-week follow-up period.&#xD;
&#xD;
      A total of 100 (50 in each group) patients will be randomized in the study and will either&#xD;
      receive the test treatment or the placebo treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D serum concentration</measure>
    <time_frame>Baseline, on days 8, 15, 22, 29 (+/-1 day), or last day of hospitalization, and finally at day 15 to 30 after hospital discharge</time_frame>
    <description>Mean change from screening to end of treatment phase in 25(OH)D3 serum concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>Baseline and up to 4 weeks after randomization on days 8, 15, 22, 29 (+/-1 day), or last day of hospitalization, and finally at day 15 to 30 after hospital discharge</time_frame>
    <description>Ordinal scale for clinical improvement as recommended by WHO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay.</measure>
    <time_frame>at day 15 to 30 after hospital discharge</time_frame>
    <description>Hospital length of stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit length of stay.</measure>
    <time_frame>at day 15 to 30 after hospital discharge</time_frame>
    <description>Intensive care unit length of stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental oxygen, non-invasive or invasive ventilation or organ support</measure>
    <time_frame>Baseline and up to 4 weeks after randomization on days 8, 15, 22, 29 (+/-1 day), or last day of hospitalization, and finally at day 15 to 30 after hospital discharge</time_frame>
    <description>Number of patients requiring supplemental oxygen, non-invasive ventilation or high flow oxygen devices, invasive mechanical ventilation or additional organ support (pressors, renal replacement therapy, extracorporeal membrane oxygenation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplemental oxygen, non-invasive or invasive ventilation or organ support</measure>
    <time_frame>at day 15 to 30 after hospital discharge</time_frame>
    <description>Duration of any organ support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of fever</measure>
    <time_frame>Last day of hospitalization, or at at day 15 to 30 after hospital discharge</time_frame>
    <description>Time until absence of fever for more than 48h without antipyretics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until negative laboratory SARS-CoV-2 test.</measure>
    <time_frame>Last day of hospitalization , or at at day 15 to 30 after hospital discharge</time_frame>
    <description>Time until negative laboratory SARS-CoV-2 test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality all causes.</measure>
    <time_frame>Last day of hospitalization , or at at day 15 to 30 after hospital discharge</time_frame>
    <description>Mortality all causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality related to Covid-19.</measure>
    <time_frame>Last day of hospitalization , or at at day 15 to 30 after hospital discharge</time_frame>
    <description>Mortality related to Covid-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers</measure>
    <time_frame>Baseline, on days 8, 15, 22, 29 (+/-1 day), or last day of hospitalization, and finally at day 15 to 30 after hospital discharge</time_frame>
    <description>Blood levels of C-reactive protein, interleukin 6 and 10, cathelicidin, white blood cells, creatinin and 1,25(OH)2-D3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Test treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Treatment: Ampoule for enteral use containing 25,000 IU/mL of cholecalciferol taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Treatment: Ampoule of placebo for enteral use containing excipient only taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Vitamin D supplementation</description>
    <arm_group_label>Test treatment</arm_group_label>
    <other_name>D-Cure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female over 18 years old (18 years inclusive).&#xD;
&#xD;
          -  Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other&#xD;
             commercial or public health assay in any specimen as diagnosed within 72 hours prior&#xD;
             to randomization.&#xD;
&#xD;
          -  Expected to survive for at least 96 hours after study entry.&#xD;
&#xD;
          -  If patient is a female of childbearing potential, patient must use an effective means&#xD;
             of birth control (oral, intravaginal or transdermal oestrogen-progestogen combined&#xD;
             hormonal contraceptives or intrauterine devices or sexual abstinence).&#xD;
&#xD;
          -  Subject or legally authorized representative understands and agrees to comply with&#xD;
             planned study procedures.&#xD;
&#xD;
          -  Subject or legally authorized representative provides informed consent prior to&#xD;
             initiation of any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women currently pregnant or breast-feeding.&#xD;
&#xD;
          -  Patients presenting acute impairment of renal function or nephrolithiasis.&#xD;
&#xD;
          -  Patients presenting hypercalcaemia and/or hypercalciuria&#xD;
&#xD;
          -  Patients presenting pseudohypoparathyroidism&#xD;
&#xD;
          -  Use of any vitamin D supplementation alone or in association at screening visit;&#xD;
&#xD;
          -  Use of any prohibited medication as detailed in the concomitant medication section&#xD;
&#xD;
          -  Patients with any sensitivity or allergy to any of the products used within this&#xD;
             clinical trial.&#xD;
&#xD;
          -  Presence of any other condition or illness, which, in the opinion of the investigator,&#xD;
             would interfere with optimal participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne-Françoise Rousseau, MD, PhD</last_name>
    <phone>+3243667495</phone>
    <email>afrousseau@chuliege.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Françoise Rousseau</last_name>
      <phone>043667495</phone>
      <email>afrousseau@chuliege.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Amrein K, Zajic P, Schnedl C, Waltensdorfer A, Fruhwald S, Holl A, Purkart T, Wünsch G, Valentin T, Grisold A, Stojakovic T, Amrein S, Pieber TR, Dobnig H. Vitamin D status and its association with season, hospital and sepsis mortality in critical illness. Crit Care. 2014 Mar 24;18(2):R47. doi: 10.1186/cc13790.</citation>
    <PMID>24661739</PMID>
  </reference>
  <reference>
    <citation>Amrein K, Litonjua AA, Moromizato T, Quraishi SA, Gibbons FK, Pieber TR, Camargo CA Jr, Giovannucci E, Christopher KB. Increases in pre-hospitalization serum 25(OH)D concentrations are associated with improved 30-day mortality after hospital admission: A cohort study. Clin Nutr. 2016 Apr;35(2):514-521. doi: 10.1016/j.clnu.2015.03.020. Epub 2015 Apr 14.</citation>
    <PMID>25935851</PMID>
  </reference>
  <reference>
    <citation>Amrein K, Schnedl C, Holl A, Riedl R, Christopher KB, Pachler C, Urbanic Purkart T, Waltensdorfer A, Münch A, Warnkross H, Stojakovic T, Bisping E, Toller W, Smolle KH, Berghold A, Pieber TR, Dobnig H. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA. 2014 Oct 15;312(15):1520-30. doi: 10.1001/jama.2014.13204. Erratum in: JAMA. 2014 Nov 12;312(18):1932.</citation>
    <PMID>25268295</PMID>
  </reference>
  <reference>
    <citation>Barlow PG, Beaumont PE, Cosseau C, Mackellar A, Wilkinson TS, Hancock RE, Haslett C, Govan JR, Simpson AJ, Davidson DJ. The human cathelicidin LL-37 preferentially promotes apoptosis of infected airway epithelium. Am J Respir Cell Mol Biol. 2010 Dec;43(6):692-702. doi: 10.1165/rcmb.2009-0250OC. Epub 2010 Jan 22.</citation>
    <PMID>20097832</PMID>
  </reference>
  <reference>
    <citation>Barnett N, Zhao Z, Koyama T, Janz DR, Wang CY, May AK, Bernard GR, Ware LB. Vitamin D deficiency and risk of acute lung injury in severe sepsis and severe trauma: a case-control study. Ann Intensive Care. 2014 Feb 24;4(1):5. doi: 10.1186/2110-5820-4-5.</citation>
    <PMID>24559079</PMID>
  </reference>
  <reference>
    <citation>Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol. 2011 Mar;50(3):194-200. doi: 10.1016/j.jcv.2010.12.006. Epub 2011 Jan 15. Review.</citation>
    <PMID>21242105</PMID>
  </reference>
  <reference>
    <citation>Braun AB, Gibbons FK, Litonjua AA, Giovannucci E, Christopher KB. Low serum 25-hydroxyvitamin D at critical care initiation is associated with increased mortality. Crit Care Med. 2012 Jan;40(1):63-72. doi: 10.1097/CCM.0b013e31822d74f3.</citation>
    <PMID>21926604</PMID>
  </reference>
  <reference>
    <citation>Cavalier E, Faché W, Souberbielle JC. A Randomised, Double-Blinded, Placebo-Controlled, Parallel Study of Vitamin D3 Supplementation with Different Schemes Based on Multiples of 25,000 IU Doses. Int J Endocrinol. 2013;2013:327265. doi: 10.1155/2013/327265. Epub 2013 Jan 28.</citation>
    <PMID>23431293</PMID>
  </reference>
  <reference>
    <citation>Abhimanyu, Coussens AK. The role of UV radiation and vitamin D in the seasonality and outcomes of infectious disease. Photochem Photobiol Sci. 2017 Mar 16;16(3):314-338. doi: 10.1039/c6pp00355a. Review.</citation>
    <PMID>28078341</PMID>
  </reference>
  <reference>
    <citation>Dancer RC, Parekh D, Lax S, D'Souza V, Zheng S, Bassford CR, Park D, Bartis DG, Mahida R, Turner AM, Sapey E, Wei W, Naidu B, Stewart PM, Fraser WD, Christopher KB, Cooper MS, Gao F, Sansom DM, Martineau AR, Perkins GD, Thickett DR. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax. 2015 Jul;70(7):617-24. doi: 10.1136/thoraxjnl-2014-206680. Epub 2015 Apr 22.</citation>
    <PMID>25903964</PMID>
  </reference>
  <reference>
    <citation>Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0. Review.</citation>
    <PMID>32169119</PMID>
  </reference>
  <reference>
    <citation>De Niet S, Coffiner M, Da Silva S, Jandrain B, Souberbielle JC, Cavalier E. A Randomized Study to Compare a Monthly to a Daily Administration of Vitamin D₃ Supplementation. Nutrients. 2018 May 23;10(6). pii: E659. doi: 10.3390/nu10060659.</citation>
    <PMID>29882841</PMID>
  </reference>
  <reference>
    <citation>Gombart AF, Pierre A, Maggini S. A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection. Nutrients. 2020 Jan 16;12(1). pii: E236. doi: 10.3390/nu12010236. Review.</citation>
    <PMID>31963293</PMID>
  </reference>
  <reference>
    <citation>Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020 Apr 2;12(4). pii: E988. doi: 10.3390/nu12040988. Review.</citation>
    <PMID>32252338</PMID>
  </reference>
  <reference>
    <citation>Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. 2015 May 29;7(6):4240-70. doi: 10.3390/nu7064240. Review.</citation>
    <PMID>26035247</PMID>
  </reference>
  <reference>
    <citation>Gruber-Bzura BM. Vitamin D and Influenza-Prevention or Therapy? Int J Mol Sci. 2018 Aug 16;19(8). pii: E2419. doi: 10.3390/ijms19082419. Review.</citation>
    <PMID>30115864</PMID>
  </reference>
  <reference>
    <citation>Han JE, Jones JL, Tangpricha V, Brown MA, Brown LAS, Hao L, Hebbar G, Lee MJ, Liu S, Ziegler TR, Martin GS. High Dose Vitamin D Administration in Ventilated Intensive Care Unit Patients: A Pilot Double Blind Randomized Controlled Trial. J Clin Transl Endocrinol. 2016 Jun;4:59-65. doi: 10.1016/j.jcte.2016.04.004. Epub 2016 May 5.</citation>
    <PMID>27419080</PMID>
  </reference>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J Cyst Fibros. 2007 Nov 30;6(6):403-10. Epub 2007 Apr 27.</citation>
    <PMID>17467345</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Anne-Françoise Rousseau</investigator_full_name>
    <investigator_title>Head of Clinic</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

